IHC testing in cholangiocarcinoma

A pathologist applies antibodies to a biopsy or surgical specimen. Each antibody binds to a particular protein, producing a staining pattern that can support or argue against a diagnosis. The report may describe markers as positive, negative, focal or diffuse. No single stain confirms every cholangiocarcinoma.

The pattern is interpreted alongside how the cells look under the microscope, where the tumour sits on imaging, and the person's clinical history. This is especially useful when a tumour in the liver could be a primary intrahepatic cholangiocarcinoma or a cancer that spread there from another organ. In some notes, however, the abbreviation may refer to intrahepatic cholangiocarcinoma; the surrounding wording should make the intended meaning clear.

Request a plain-language explanation of the final pathology diagnosis rather than interpreting one marker alone. Ask whether the sample was sufficient and whether comparison with previous tissue is needed. IHC helps classify the cancer, while separate molecular testing may look for tumour changes that can guide targeted therapy.

The multidisciplinary team combines pathology with scans to establish the primary site and extent of disease. Those findings, liver function, symptoms and general health shape whether surgery or systemic treatment is considered.

An IHC result itself does not create an emergency. After a biopsy, seek prompt medical advice for increasing pain, spreading redness, persistent bleeding, fever, shortness of breath or feeling faint. Independently of testing, fever or chills with jaundice and worsening abdominal pain requires urgent assessment because bile duct blockage may be complicated by infection.

Ask what IHC means in your report, which diagnosis the overall staining pattern supports, and whether another possible primary cancer has been excluded. It is also reasonable to ask whether more tissue, expert pathology review or molecular profiling would change the treatment choices.